2016
Titularprofessor der Universität Bern

seit 2013
Leiter Medizinische Klinik, Chefarzt Tumorzentrum und Chefarzt Onkologie, St. Claraspital Basel

2011
Habilitation

2009 – 2010
Diplomkurs Health Care Management, Hochschule St. Gallen

2008 – 2012
Leitender Arzt, Kantonsspital St. Gallen

2005 – 2007
Oberarzt mit besonderer Funktion, Kantonsspital St. Gallen

2004 – 2012
Disease-spezifische Leitung gastrointestinaler Tumore, Kantonsspital St. Gallen

2003 – 2012
Leiter onkologisch-hämatologisches Ambulatorium, Kantonsspital St. Gallen

2003 – 2012
Konsiliararzt, Kantonsspital Herisau

2003 – 2012
Koordination genetische Sprechstunde, Kantonsspital St. Gallen

2001 – 2004
Oberarzt, Kantonsspital St. Gallen

2000
Facharzttitel Innere Medizin und Medizinische Onkologie

1999 – 2000
Fachassistenzarzt Onkologie/Hämatologie, Kantonsspital St. Gallen

1999
Oberarzt Innere Medizin, Thurgauer-Schaffhausner Höhenklinik, Davos

1997 – 1999
Fachassistenzarzt Innere Medizin, Kantonsspital St. Gallen

1995 – 1997
Klinischer Forschungsarzt Onkologie/Hämatologie, Kantonsspital St. Gallen

1994 – 1995
Landeskrankenhaus Bregenz

1994
Landeskrankenhaus Feldkirch

1986 – 1993
Medizinstudium an der Universität Innsbruck

• ESMO
• ASCO
• Central European Society for Anticancer Drug Research
• Schweizerische Senologiegesellschaft
• International Breast Cancer Study Group

• Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R: Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). 2022: Cancers (Basel) 14(9): 2191
• Adamina M, Warlaumont M, Berger MD, Däster S, Delaloye R, Digklia A, Gloor B, Fritsch R, Koeberle D, Koessler T, Lehmann K, Müller P, Peterli R, Ris F, Steffen T, Weisshaupt CS, Hübner M: Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin. 2022: Cancers (Basel) 14(17): 4275.
• Truninger K, Luigli A, Koeberle D: Nachsorge nach koloskopischen Polypektomie und Therapie des kolorektalen Karzinoms. 2022: Swiss Medical Forum 22(21-22): 349-355.
• Bastian S, Joerger M, Baertschi D, Holer L, Guckenberger M, Jochum W, Koeberle D, Siebenhüner AR, Wicki A, Berger MD, Winterhalder RC, Largiadèr CR, Löffler M, Mosna- Firlejczyk K, Fischer Maranta A, von Moos R for the Swiss Group for Clinical Cancer Research (SAKK): Neoadjuvant treatment with Regorafenib and Capecitabine combined with radiotherapy in locally advanced rectal cancer. A multicenter phase Ib trial (RECAP) 2022: SAKK 41/16. ESMO Congress Paris.
• Koeberle D, Fritsch R: Targeting HER2 in Biliary Tract Carcinomas: Challenges and Opportunities. 2021: Oncol. Res. Treat 44(1–2).
• Köberle D: Systemtherapie des hepatozellulären und cholangiozellulären Karzinoms. 2021: info@onkologie 11(3).
• McNamara MG, Lopes A, Wasan H, Malka D, Goldstein D, Shannon J, Okusaka T, Knox JJ, Wagner AD, André T, Cunningham D, Moehler M, Jensen LH, Koeberle D, Bekaii-Saab T, Bridgewater J, Valle JW.. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. J Hepatol. 2020 Nov;73(5):1109-1117. doi: 10.1016/j.jhep.2020.05.014.
• Löffler M, Schill C, Köberle D. ASCO-GI-Symposium 2020. info@oncology 2020, Vol 10, Ausgabe 2
• Köberle D. ASCO-Guideline 2020: Behandlung des lokal fortgeschrittenen Oesophaguskarzinoms. info@oncology 2020, Vol 10, Ausgabe 7
• Köberle D. and Krauthammer M: Onconavigator and integration of real-world data (RWD) into the clinical evidence. Cancer Research in Switzerland 2020; 67-71
• Fox M, Meyer-Gerspach AC, Wendebourg MJ, Gruber M, Heinrich H, Sauter M, Wölnerhanssen B, Koeberle D, Juengling F; Effect of cocoa on the brain and gut in healthy subjects: a randomized controlled trial. Br J Nutr. 2019 Mar: 121(6): 654–661.
• Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M; A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Sep 1; 30(9): 1487–1495
• Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R;Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. J Geriatr Oncol. 2019 Mar; 10(2): 304–310.
• Fox M, Meyer-Gerspach AC, Wendebourg MJ, Gruber M, Heinrich H, Sauter M, Wölnerhanssen B, Köberle D, Jüngling F. The effect of cocoa on the brain and the gut in healthy subjects: a randomized controlled trial. British Journal of Nutrition, 2018 Dec; 1-22.
• Löffler M, Köberle D. Info@Onkologie; Behandlung des Kolonkarzinoms im Alter. Vol 8: 19–22.
• Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC, Koeberle D, Horber D, Bastian S, Kueng M, Saletti P, Helbling D, Baertschi D, Lugli A, Bernhard J, Andrieu C, von Moos R; Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF- wildtype metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41 / 10. Swiss Group for Clinical Cancer Research. J Geriatr Oncol. 2018 Dec 14: S1879-4068(18)30267-4.
• Montemurro M., Cioffi A., Dômont J., Rutkowski P., Roth AD.,von Moos R., Inauen R., Toulmonde M., Burkhard RO., Knuesli C., Bauer S., Cassier P., Schwarb H., Le Cesne A., Koeberle D., Bärtschi D., Dietrich D., Biaggi C., Prior J, Leyvraz S. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56 / 07). Cancer. 2018 Apr 1; 124(7): 1449–1454
• Moos R., Koeberle D., Schacher S., Hayoz S., Winterhalder RC., Roth A., Bodoky G., Samaras P., Berger MD., Rauch D., Saletti P., Plasswilm L., Zwahlen D., Meier UR., Yan P., Izzo P., Klingbiel D., Bärtschi D., Zaugg K.; Swiss Group for Clinical Cancer Research (SAKK): Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I / II trial (SAKK 41 / 08). Eur J Cancer (2018); Jan; 89: 82–89.
• Burmeister K., Quagliata L., Andreozzi M., Eppenberger-Castori S., Matter M., Perrina V., Grobholz R., Jochum W., Horber D., Moosmann P., Lehmann F., Köberle D., Ng C., Piscuoglio S., Tornillo L., Terracciano L.: Vascular Endothelial Growth Factor A Amplification in Colorectal Cancer is Associated with Reduced M1 and M2 Macrophages and Diminished PD-1-Expressing Lymphocytes. PLoS One (2017); 12(4): e0175563